CellAct Pharma GmbH

CellAct Pharma is focused on the development of innovative therapeutics for the treatment of diseases with high unmet need, especially certain cancers and inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. CellAct's drug candidates target and modulate human molecules that have specific functions in tumour growth and immune response. A small molecule compound, CAP7.1 which targets topoisomerase II, is currently in a clinical Phase I study for the treatment of cancer. CellAct also develops antibodies against cell surface molecules in lymphocytes to treat cancer and inflammation.